SYNTAX Substudy Shows Positive Outcomes for Left Main Patients Treated With TAXUS(R) Express2(R) Stent System

...he results support previously announced outcomes with PCI and CABG in patients with left main disease." The safety and effectiveness of the TAXUS express2 Stent System have not been established in patients with left main or three-vessel disease. Boston Scientific is a worldwide developer, manufactur...

Boston Scientific Announces Schedule for EuroPCR 2009

...m run will begin at 7:00 a.m. on Wednesday May 20th, and participants can register onsite at the Boston Scientific exhibit booth. TAXUS, Express, express2 and PROMUS are trademarks of Boston Scientific Corporation or its affiliates. The PROMUS Stent is a private-labeled XIENCE V Everolimus-Eluting Coron...

Express2 in Medical Technology

SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(R) Stent System More Cost Effective Than Bypass Surgery in Patients With Complex Coronary Artery Disease

...r Event rate, including all-cause death, stroke, MI and repeat revascularization) was higher for PCI. The safety and effectiveness of the TAXUS express2 Stent System have not been established in patients with left main or three-vessel disease. Boston Scientific is a worldwide developer, manufactur...

Abbott's Market-Leading XIENCE V(R) Shows Increasing Clinical Advantages Over TAXUS(R) Express2(TM)/TAXUS(R) Liberte(TM) Between Two and Three Years

...the TAXUS(R) Express2(TM) Paclitaxel-Eluting Coronary Stent System / TAXUS(R) Liberte(TM) Paclitaxel-Eluting Coronary Stent System (TAXUS). Both TAXUS express2 (73 percent of lesions) and TAXUS Liberte (27 percent of lesions) were used as controls in the SPIRIT II trial. The data also showed that patients tre...

SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(TM) Stents More Cost Effective Than Bypass Surgery in Many Patients With Complex Coronary Artery Disease

... to treat some or all of these 'surgical' patients with PCI using the TAXUS express2 stent. The cost-effectiveness analysis compared the relative benefits ...ns a score to each patient. The safety and effectiveness of the TAXUS express2 Stent System have not been established in patients with left main or three-...

New England Journal of Medicine Publishes Results from Boston Scientific's Landmark SYNTAX(TM) Trial

...AX Score results had similar 12-month combined MACCE rates to CABG patients (13.6 percent for PCI and 14.7 percent for CABG, p=0.71). The TAXUS express2 Paclitaxel-Eluting Coronary Stent System used in the SYNTAX trial has now been replaced by the Company's second-generation TAXUS(R) Liberte(R) Paclita...

SYNTAX Data Show Comparable Safety for Complex Patients Treated with TAXUS(R) Express2(TM) Stents and Bypass Surgery

...ABG was the preferred option, then patients were placed in one of two parallel registries for PCI or CABG. The safety and effectiveness of the TAXUS express2 Stent System has not been established in patients with left main, multi-vessel disease, chronic total occlusion, lesions at a bifurcation/trifurcation...

Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008

...ents with left main (LM) and three-vessel disease (3VD) from the SYNTAX trial, which compares percutaneous coronary intervention (PCI) using the TAXUS express2 Stent System to coronary artery bypass graft (CABG) surgery in these most complex patient groups. In addition, the Company will present two-year resul...

Boston Scientific PROMUS(TM) and TAXUS(R) Stents Continue Strong Performance in Safety and Efficacy Measures

...th an anticipated U.S. launch in 2008. The safety and efficacy of the TAXUS express2 Stent System have not been established in patients with diabetes, long lesions and small vessels. SPIRIT is sponsored by Abbott. TAXUS, express2 and PROMUS are trademarks of Boston Scientific Corporation or its affiliate...

Boston Scientific to Release Broad Range of Clinical Trial Data Reinforcing Safety and Efficacy of Taxus(R) Coronary Stent Systems at TCT 2007

...fety and clinical outcomes data from the TAXUS express2 Paclitaxel-Eluting Stent System in the treatment o...term safety and clinical efficacy of the TAXUS express2 Paclitaxel-Eluting Coronary Stent System versu...S IV clinical trial, which evaluates the TAXUS express2 Paclitaxel-Eluting Coronary Stent System versus ba...

Boston Scientific Announces Schedule for EuroPcr 2007

...th the XIENCE V (PROMUS) Stent or the TAXUS express2 Stent. The SPIRIT family of trials is designed to...tific as the PROMUS Stent, versus the TAXUS express2 Paclitaxel-Eluting Coronary Stent System in...catheterization labs. PROMUS, TAXUS, Express and express2 are trademarks of Boston Scientific Corporation or...

SPIRIT Clinical Data Reaffirm Strength of Taxus and Promus Drug-Eluting Coronary Stent Systems

... U.S. and not yet approved for sale. It is currently under FDA review with an anticipated U.S. launch in 2008. SPIRIT is sponsored by Abbott. TAXUS, express2 and PROMUS are trademarks of Boston Scientific Corporation or its affiliates. XIENCE is a trademark of Abbott Laboratories group of companies. Bosto...

Express2 in Medical Products

TAXUS Express2 Monorail Paclitaxel-Eluting Coronary Stent System

Description: The TAXUS Express Paclitaxel-Eluting Coronary Stent System is indicated for improving luminal diameter for the treatment of de novo lesions = 28 mm in length in native coronary arteries = 2.5 to = 3.75 mm in diameter....
Company:Boston Scientific Corporation

TAXUS Express2 Over-the-wire Paclitaxel-Eluting Coronary Stent System

Description: The TAXUS Express Paclitaxel-Eluting Coronary Stent System is indicated for improving luminal diameter for the treatment of de novo lesions = 28 mm in length in native coronary arteries = 2.5 to = 3.75 mm in diameter....
Company:Boston Scientific Corporation

Express2 in Biological Technology

Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009

...l is granted. TAXUS Liberte is the only second-generation drug-eluting stent approved for use in Japan. The TAXUS Liberte stent will replace the TAXUS express2 stent, marketed in Japan since May 2007. Financial and Strategic Alternatives Process. Over the last two years, revenue in our Pharmaceutical Tec...

Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008

...ed that BSC had received approval from the FDA to market and sell the Taxus express2 Atom(TM) Paclitaxel-Eluting Coronary Stent System in the United States. We ...007, and will compare the TAXUS Element Stent to the prior-generation TAXUS express2 Stent marketed in the United States since 2004. Financial Informa...

Boston Scientific Announces Japanese Approval for TAXUS(R) Liberte(R) Drug-Eluting Stent System

...ost-approval registries. More than 4.6 million TAXUS Stent Systems have been implanted globally. The TAXUS Liberte Stent will replace the TAXUS express2 Stent, which was launched in Japan in May 2007. It has been approved for sale in the United States, Europe and other international markets. Bo...

Video: Boston Scientific Announces FDA Approval of Second-Generation TAXUS(R) Liberte(R) Drug-Eluting Stent

...Officer of Boston Scientific. The TAXUS stent systems -- both Liberte and express2 -- have been evaluated by the industry's most extensive randomized, control...king them the world's most frequently used drug-eluting stents. The TAXUS express2 stent (not the newer TAXUS Liberte stent) was used as the control against t...

Boston Scientific Announces FDA Approval of TAXUS(R) Express2(TM) Atom(TM) Stent System, First Drug-Eluting Stent For Small Vessels

...onary Stent System for the treatment of in-stent restenosis in bare-metal stents. This is the first such approval granted by the FDA, making the TAXUS express2 Stent System the only drug-eluting stent approved in the United States for the treatment of in-stent restenosis in bare-metal stents. "The TAXUS Exp...

Landmark SYNTAX Trial Reports Comparable Safety Outcomes for Complex Patients Treated With TAXUS(R) Express2(TM) Stents or Bypass Surgery

...nd location, relying on data from the SYNTAX trial as well as information collected through other sources. The safety and effectiveness of the TAXUS express2 Stent System has not been established in patients with left main or three-vessel disease. Boston Scientific is a worldwide developer, manufacturer a...

Boston Scientific Announces Schedule for ACC 2008

...ients and non-diabetics treated with the TAXUS express2 Stent. The results will be presented at 8:00 ...erm safety and effectiveness data of the TAXUS express2 Stent in more complex patients treated in routine ...vascularization in Real-World Use of the TAXUS express2 Paclitaxel-Eluting Stent: Insights from the 7,...

ARRIVE Registry Analysis Demonstrates Continued Safety and Efficacy of TAXUS(R) Stent in Complex Real-World Patients

...o years in complex patients treated with the TAXUS express2 Stent. Analysis of the data was presented at the C... determine if the safety and efficacy of the TAXUS express2 Stent System demonstrated in simpler randomized cl...achytherapy. The safety and efficacy of the TAXUS express2 stent system have not been established in the...